Sunshine Biopharma, Inc. (SBFMW) Stock Price & Analysis
Sunshine Biopharma, Inc. (SBFMW) — price $0.0251 (0.00%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Sunshine Biopharma, Inc. · SBFMW
Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company focused on developing innovative anticancer and antiviral drugs.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0251 |
| Change on the day | 0.00% |
| 52-week range | $0.016 – $0.6498 |
| Shares traded on the day | 300 |
Price & events
Watch the SBFMW film — every key number, told as a short cinematic story
~2 min · open the film
What is Sunshine Biopharma (SBFMW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sunshine Biopharma, Inc. (SBFMW) is the company analyzed here. It employs 50 people and is led by Steve N. Slilaty. In Q2 FY2026 it reported revenue of $9M and net income of -$2M.
What do the latest results show for Sunshine Biopharma (SBFMW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $9M. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $9M | -$2M | -$1.15 (diluted) |
| Q1 FY2026 | $8M | -$1M | -$2.50 (diluted) |
| Q4 FY2025 | $9M | -$2M | -$4.60 (diluted) |
| Q3 FY2025 | $9M | -$883,820 | -$1.90 (diluted) |
What are the financial strengths and risks for Sunshine Biopharma (SBFMW)?
Short answer · as of
The distress and quality screens read Altman Z -27.27 · Piotroski F 3. Trailing ratios: ROE -24.2% · ROA -17.3% · current ratio 5.46.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -27.27 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-24.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Aug 7, 2026 (coverage not recorded)
- Transactions
- 2
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Sunshine Biopharma (SBFMW)?
- Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
- EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
- Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
- EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0251 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T19:24:40.369Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 300 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $9M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 2 transactions · 0 purchases, 0 sales, 2 other transactions · 1 identified insiders · available records within the last 180 days, newest dated Aug 7, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.016 – $0.6498 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 50 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Steve N. Slilaty | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-04 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -27.27 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-08-14 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -24.2% · ROA -17.3% · current ratio 5.46 | UNRECORDED | Stored key metrics — Captured 2026-10-02 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.